Work

Lebrikizumab, a High-Affinity IL-13 Inhibitor, Improves Clinical Manifestations in Moderate-to-Severe Atopic Dermatitis: Primary Results From a Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging, Phase 2b Study

Year: 2019

Type: article

Abstract: not available.

Source: SKIN The Journal of Cutaneous Medicine

DOI: 10.25251/skin.3.supp.41

Authors: E Guttman-Yassky, A Blauvelt, L.F. Eichenfield, A Paller, A Armstrong, J Drew, R Gopalan, E Simpson

Institutions: Icahn School of Medicine at Mount Sinai, Oregon Medical Research Center, University of California San Diego, Rady Children's Hospital-San Diego, Northwestern University, University of Southern California, Dermira (United States), Oregon Health & Science University

Language: English

Topic: Dermatology and Skin Diseases

Subfield: Dermatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

OpenAlex ID: W2984707295

FWCI: 0.868

Cites: 5

Cited by: 4

Related to: 10